Barry E Greene
President and CEO, Director at Sage Therapeutics, Inc. (SAGE)
Barry E Greene has filed 19 insider reports with the SEC since May 2021, as director at Dyne Therapeutics, Inc. (DYN), director at Karyopharm Therapeutics Inc. (KPTI) and president and CEO and director at Sage Therapeutics, Inc. (SAGE). Barry E Greene made no open-market purchases or sales in the last 12 months. The latest filing, on June 23, 2026, reports grant or award at Dyne Therapeutics, Inc. (DYN).
- Filings
- 19
- Companies
- 3
- Bought on market
- $2.02M
- Sold on market
- None
Companies where Barry E Greene is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Directorsince June 2026 | $15.50 | Jun 23, 2026 | |||||
| Director | 16,415 | $0.0174 | May 26, 2026 | ||||
| President and CEO, Director | 0 | $2.02M | $42.94 | Jul 31, 2025 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Jun 22, 2026DYNSEC Form 4 filed by Director Greene Barry EForm 4Grant or award
- Jun 22, 2026DYNBarry E Greene became an insiderForm 3New insider
- May 21, 2026KPTIDirector Greene Barry E was granted 15,508 shares, increasing direct ownership by 1,710% to 16,415 unitsForm 4Grant or award
- Jul 31, 2025SAGEPresident and CEO Greene Barry E returned 53,229 shares to the company, closing all direct ownership in the companyForm 4Sale back to the companyTender of shares in a change of control
- May 28, 2025KPTISEC Form 4 filed by Director Greene Barry EForm 4Grant or award
- Jan 16, 2025SAGESEC Form 4 filed by President and CEO Greene Barry EForm 4Grant or award
- Aug 5, 2024SAGEPresident and CEO Greene Barry E was granted 50,400 shares and covered exercise/tax liability with 12,273 shares, increasing direct ownership by 81% to 85,067 unitsForm 4Grant or awardShares withheld for taxes or exercise price
- May 29, 2024KPTISEC Form 4 filed by Greene Barry EForm 4Grant or award
- Feb 13, 2024SAGESEC Form 4 filed by Greene Barry EForm 4Grant or award
- Aug 4, 2023SAGESEC Form 4 filed by Greene Barry EForm 4Grant or award
- May 24, 2023KPTISEC Form 4 filed by Greene Barry EForm 4Grant or award
- Feb 13, 2023SAGESEC Form 4 filed by Greene Barry EForm 4Grant or award
- Nov 10, 2022+$500KSAGESEC Form 4: Greene Barry E bought $500,022 worth of shares (14,500 units at $34.48), increasing direct ownership by 45% to 46,940 unitsForm 4Open-market purchase
- Aug 11, 2022KPTISEC Form 4: Greene Barry E exercised 7,576 shares at a strike of $1.49, increasing direct ownership by 126% to 13,606 unitsForm 4Exercise or conversion of a derivative
- May 19, 2022KPTISEC Form 4 filed by Greene Barry EForm 4Grant or award
- Feb 11, 2022SAGESEC Form 4 filed by Greene Barry EForm 4Grant or award
- Aug 5, 2021+$1.02MSAGESEC Form 4: Greene Barry E bought $1,020,054 worth of Common Stock (23,640 units at $43.15), increasing direct ownership by 269% to 32,440 unitsForm 4Open-market purchase
- Jun 16, 2021+$496KSAGESEC Form 4: Greene Barry E bought $495,627 worth of Common Stock (8,800 units at $56.32)Form 4Open-market purchase
- May 21, 2021KPTISEC Form 4 filed by Greene Barry EForm 4Grant or award
Compare Barry E Greene with
- Barry E Greene vs Johanna Friedl-Naderer1 shared
- Barry E Greene vs Douglas Kerr1 shared
- Barry E Greene vs John Cox1 shared
- Barry E Greene vs Erick Lucera1 shared
- Barry E Greene vs Kristin Abate1 shared
- Barry E Greene vs Jason P Rhodes1 shared
Other insiders at the same companies
- Johanna Friedl-NadererDYN
- Douglas KerrDYN
- John CoxDYN
- Erick LuceraDYN
- Kristin AbateKPTI
- Jason P RhodesDYN
- Atlas Venture Opportunity Fund I, L.P.DYN
- Atlas Venture Fund XI, L.P.DYN
- Stuart PoultonKPTI
- Dirk KerstenDYN
- Atlas Venture Associates Xi, L.P.DYN
- Edward HurwitzDYN
- David Charles LubnerDYN
- Carlo IncertiDYN
- Catherine Stehman-BreenDYN
- Brian S PosnerDYN
Questions about Barry E Greene
- What is Barry E Greene's role at Sage Therapeutics, Inc.?
- Barry E Greene reports to the SEC as president and CEO and director at Sage Therapeutics, Inc. (SAGE), according to the latest filing on July 31, 2025. Barry E Greene has also filed as director at Dyne Therapeutics, Inc. (DYN) and director at Karyopharm Therapeutics Inc. (KPTI).
- How many shares does Barry E Greene own?
- After the latest filing that states it, Barry E Greene directly owned 16,415 shares of Karyopharm Therapeutics Inc. (KPTI). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Barry E Greene bought or sold stock recently?
- The most recent open-market purchase was on November 10, 2022: bought 14,500 shares of Sage Therapeutics, Inc. (SAGE) for $500K at an average of $34.48.
- How do I get alerts when Barry E Greene files?
- Follow Barry E Greene on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Barry E Greene (SEC CIK 0001291963). Totals count each trade once, skipping amendments whose original is on file, from May 21, 2021 on. View on SEC EDGAR · Get this as JSON